1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001.
Saved in:
| Title: | 1114P First-line lenvatinib + pembrolizumab (L + P) vs chemotherapy (CT) for advanced or recurrent endometrial cancer (EC): Additional 1-year follow-up results from ENGOT-en9/LEAP-001. |
|---|---|
| Authors: | Akıllı, H.1 (AUTHOR), Moore, R.G.2 (AUTHOR), Marth, C.3 (AUTHOR), Redondo, T. Diaz4 (AUTHOR), Korach, J.5 (AUTHOR), Stillie, A.6 (AUTHOR), Baurain, J-F.7 (AUTHOR), Mach, P.8 (AUTHOR), Cadoo, K.9 (AUTHOR), Bidzinski, M.10 (AUTHOR), Ariyoshi, K.11 (AUTHOR), Wu, X.12 (AUTHOR), Frentzas, S.13 (AUTHOR), Mattar, A.14 (AUTHOR), Slomovitz, B.M.15 (AUTHOR), Yao, L.16 (AUTHOR), Mckenzie, J.17 (AUTHOR), Meng, R.18 (AUTHOR), Gilbert, L.19 (AUTHOR), Makker, V.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS741-S741. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1751 |
